Bodd, M., Locke, S., Antonia, S., Crawford, J., Hartman, J., Herring, K., … LeBlanc, T. (2021). 636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study. In Regular and Young Investigator Award Abstracts (pp. A665–A665). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2021-sitc2021.636

Bodd, Monica, Susan Locke, Scott Antonia, Jeffrey Crawford, John Hartman, Kris Herring, Neal Ready, et al. “636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study.” In Regular and Young Investigator Award Abstracts, A665–A665. BMJ Publishing Group Ltd, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.636.

Bodd M, Locke S, Antonia S, Crawford J, Hartman J, Herring K, et al. 636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A665–A665.

Bodd, Monica, et al. “636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2021, pp. A665–A665. Crossref, doi:10.1136/jitc-2021-sitc2021.636.

Bodd M, Locke S, Antonia S, Crawford J, Hartman J, Herring K, Ready N, Stinchcombe T, Troy J, Williams C, Wolf S, Clarke J, LeBlanc T. 636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A665–A665.